Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22439041 | 0.91 | KDM1A (0.41) | KDM1AKCNH2RCOR1 | |
| SCHEMBL17478868 | 0.84 | SLC6A4 (0.36) | SLC6A3SLC6A4 | |
| SCHEMBL30034514 | 0.81 | SLC6A4 (0.52) | SLC6A3SLC6A4 | |
| SCHEMBL1650477 | 0.81 | SLC6A4 (0.52) | SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL18742706 | 0.79 | SLC6A4 (0.50) | SLC6A3SLC6A4 | |
| SCHEMBL18769490 | 0.77 | — | — | |
| SCHEMBL24267986 | 0.76 | SLC6A4 (0.37) | SLC6A3SLC6A4 | |
| SCHEMBL22928806 | 0.76 | ESR1 (0.35) | — | |
| SCHEMBL31474102 | 0.76 | KDM1A (0.38) | KDM1AKCNH2KDM1BRCOR1SLC6A3 | |
| SCHEMBL18742767 | 0.76 | SLC6A3 (0.56) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119233976-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-01-04 | — | — | US | disclosed |
| EP-4200281-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-06-28 | — | — | EP | disclosed |
| CN-116249696-A | Pyrimidinone compounds and use thereof | 和记黄埔医药（上海）有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021013833-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | ENPP2, MYT1, INMT | KDM1A 229/4885KCNH2 4131/4885KDM1B 392/4885 |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KDM1A 3210/4885KCNH2 4582/4885KDM1B 2718/4885 |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | TYMP, DPYD, DHFR | KDM1A 3124/4885KCNH2 2992/4885KDM1B 3151/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | KDM1A 3210/4885KCNH2 4582/4885KDM1B 2718/4885 |
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | CYP2D6, TPMT, CYP2B6 | KDM1A 2855/4885KCNH2 426/4885KDM1B 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.